In the latest post on the the IVI-sponsored Health Affairs blog series, Donald Light offers a response to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach focusing on the excess of US drug pricing over prices in other developed countries. Light argues that the myth of the “foreign free-rider,” in which the US covers the majority of new drug development costs for other countries, is simply not true—and he urges the Trump administration to call this bluff being perpetuated by drug manufacturers.
Read the full article here.
About the Health Affairs/IVI Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
